Scientists of the CSIR-Centre for Cellular and Molecular Biology (CSIR-CCMB), Hyderabad, who have analysed more than 2000 genomes of the novel SARS-CoV-2 virus, have found that the clade or genetic group circulating in India has 70% similarity with the major strain around the world. The similarity in viral genome globally means a vaccine or a drug targeting the mutation in A2a clade will work with the same effectiveness all over the world.
Viruses have different clades which need different vaccines or drugs to target them. If the clade is common, then one vaccine or drug is sufficient to fight it.
CSIR-CCMB scientists have found that the clade that is now dominant in India is A2a, which has a similarity with 70% of genomes studied worldwide. The earlier dominant clade in India, A3i, has waned, resulting in the increase of A2a genetic group of the pandemic virus. The CCMB study says there is no evidence to state that this mutation is clinically a more difficult one. No clade at present has been conclusively shown to be associated with a more severe form of Covid-19 or an increased risk of death.
The findings of the study carried out with scientists from CSIR-Institute of Genomics and Integrative Biology as collaborators, are now peer-reviewed and published in the journal Open Forum Infectious Diseases published by the Oxford University Press.